TEVA-ATAZANAVIR 150 MG
ATAZANAVIR (ATAZANAVIR SULFATE) : 150 MG · DIN 02443791 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-ATAZANAVIR?
TEVA-ATAZANAVIR 150 MG contains ATAZANAVIR (ATAZANAVIR SULFATE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02443791, held by TEVA CANADA LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Apr-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02443791 |
|---|---|
| Brand name | TEVA-ATAZANAVIR |
| Generic / active ingredient | ATAZANAVIR (ATAZANAVIR SULFATE) : 150 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 150 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AE08 ATAZANAVIR |
| AHFS class | 52:28.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Apr-2017 |
| Original market date | 2016-02-01 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J05AE08 ATAZANAVIR. 6 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MYLAN-ATAZANAVIR | 150 MG | CAPSULE | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02456877 |
| MYLAN-ATAZANAVIR | 200 MG | CAPSULE | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02456885 |
| MYLAN-ATAZANAVIR | 300 MG | CAPSULE | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02456893 |
| TEVA-ATAZANAVIR | 200 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02443813 |
| TEVA-ATAZANAVIR | 300 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02443821 |
| APO-ATAZANAVIR | 150 MG | CAPSULE | APOTEX INC | APPROVED | DIN 02479249 |
| APO-ATAZANAVIR | 200 MG | CAPSULE | APOTEX INC | APPROVED | DIN 02479257 |
| APO-ATAZANAVIR | 300 MG | CAPSULE | APOTEX INC | APPROVED | DIN 02479265 |
| JAMP ATAZANAVIR | 150 MG | CAPSULE | JAMP PHARMA CORPORATION | DORMANT | DIN 02513102 |
| JAMP ATAZANAVIR | 200 MG | CAPSULE | JAMP PHARMA CORPORATION | DORMANT | DIN 02513110 |
Who else supplies ATAZANAVIR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ATAZANAVIR appears in 40 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.